Loading…
Docmode Health Technologies (DHTL)₹21.20−3.85%E-Learning
In the Mar 2026 quarter (consolidated), Docmode Health Technologies reported sales of ₹7.64 Cr, down 64.1% from Mar 2025, and net profit of −₹0.06 Cr. For the year to Mar 2026, sales were ₹25.31 Cr and net profit −₹0.12 Cr.
Company filings, consolidated accounts; latest reported quarter Mar 2026
| Mar 2023 | Sep 2023 | Mar 2024 | Sep 2024 | Mar 2025 | Sep 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Sales | 19.94 | 23.52 | 16.34 | 20.35 | 21.26 | 17.80 | 7.64 |
| Expenses | 18.60 | 20.90 | 17.24 | 20.56 | 21.99 | 17.06 | 8.84 |
| Operating Profit | 1.43 | 2.71 | −0.82 | −0.11 | −0.61 | 0.79 | −1.15 |
| OPM % | 7.1% | 11.5% | −5.1% | −0.6% | −2.9% | 4.5% | −15.2% |
| Other Income | 0.04 | 0.05 | 0.06 | 0.83 | 0.08 | 0.06 | 1.31 |
| Interest | 0.71 | 0.85 | 0.83 | 1.10 | 0.84 | 0.86 | 0.12 |
| Depreciation | 0.00 | 0.01 | 0.00 | 0.13 | 0.15 | 0.10 | 0.11 |
| Profit before tax | 0.77 | 1.91 | −1.58 | −0.52 | −1.53 | −0.10 | −0.06 |
| Tax % | 18.4% | 29.2% | −25.8% | 2.0% | 3.9% | 0.0% | 0.0% |
| Net Profit | 0.60 | 1.35 | −1.16 | −0.51 | −1.57 | −0.08 | −0.06 |
| EPS (Rs) | 2.65 | 5.92 | −3.71 | −1.64 | −5.02 | −0.28 | −0.21 |
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Sales | 6.92 | 7.08 | 12.38 | 32.75 | 39.78 | 41.53 | 25.31 |
| Expenses | 6.56 | 6.24 | 10.55 | 29.17 | 38.08 | 42.44 | 25.78 |
| Operating Profit | 0.38 | 0.86 | 1.88 | 3.73 | 1.87 | −0.67 | −0.33 |
| OPM % | 5.6% | 12.2% | 15.2% | 11.3% | 4.7% | −1.6% | −1.4% |
| Other Income | 0.00 | 0.00 | 0.00 | 0.09 | 0.13 | 0.92 | 1.39 |
| Interest | 0.00 | 0.20 | 0.39 | 1.12 | 1.67 | 1.93 | 0.98 |
| Depreciation | 0.04 | 0.03 | 0.01 | 0.01 | 0.01 | 0.29 | 0.22 |
| Profit before tax | 0.34 | 0.63 | 1.51 | 2.70 | 0.33 | −1.98 | −0.13 |
| Tax % | −6.1% | 14.0% | 38.7% | 27.5% | 44.1% | 3.0% | −7.2% |
| Net Profit | 0.33 | 0.54 | 0.91 | 1.94 | 0.18 | −2.02 | −0.12 |
| EPS (Rs) | — | — | — | 8.48 | 0.59 | −6.45 | −0.40 |
| Dividend payout % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Equity Capital | 0.02 | 0.02 | 0.02 | 2.30 | 3.15 | 3.15 | 3.15 |
| Reserves | −0.10 | 0.47 | 1.39 | 1.19 | 7.26 | 5.23 | 5.09 |
| Borrowings | 0.02 | 1.05 | 4.82 | 8.47 | 9.15 | 6.80 | 3.72 |
| Other Liabilities | 1.97 | 4.14 | 3.87 | 5.08 | 10.64 | 24.17 | 21.56 |
| Total Liabilities | 1.91 | 5.68 | 10.10 | 17.04 | 30.20 | 39.35 | 33.52 |
| Fixed Assets | 0.16 | 0.17 | 0.51 | 2.08 | 0.98 | 1.23 | 0.99 |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 8.51 | 11.59 | 13.47 |
| Investments | 0.00 | 0.09 | 1.24 | 1.19 | 1.25 | 1.28 | 1.29 |
| Other Assets | 1.75 | 5.42 | 8.35 | 13.77 | 19.46 | 25.25 | 17.77 |
| Inventories | 1.33 | 3.27 | 2.49 | 2.52 | 2.50 | 11.16 | 7.74 |
| Trade receivables | 0.00 | 1.35 | 3.81 | 8.28 | 11.46 | 9.23 | 7.43 |
| Cash & equivalents | 0.08 | 0.30 | 0.13 | 0.38 | 3.09 | 1.83 | 0.17 |
| Total Assets | 1.91 | 5.68 | 10.10 | 17.04 | 30.20 | 39.35 | 33.52 |
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Cash from operating activity | 0.16 | −0.49 | −2.04 | −0.82 | 4.50 | 6.67 | 4.29 |
| Cash from investing activity | −0.21 | −0.14 | −1.53 | −1.58 | −7.56 | −3.68 | −1.90 |
| Cash from financing activity | 0.02 | 0.85 | 3.42 | 2.66 | 5.77 | −4.29 | −4.07 |
| Net cash flow | −0.02 | 0.20 | −0.16 | 0.24 | 2.71 | −1.26 | −1.65 |
| Capex | 0.19 | 0.03 | 0.36 | 1.59 | 7.41 | 3.64 | 1.87 |
| Free cash flow | −0.02 | −0.53 | −2.41 | −2.42 | −2.90 | 3.02 | 2.41 |
| CFO / OP % | 46.0% | −56.9% | −103.0% | −22.0% | 239.1% | −1,000.9% | −1,265.0% |
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Debtor days | 0 | 69 | 111 | 91 | 104 | 80 | 106 |
| Inventory days | 120 | 668 | 500 | — | — | — | 633 |
| Days payable | 60 | 512 | 323 | — | — | — | 288 |
| Cash conversion cycle | 61 | 227 | 291 | 92 | 105 | 81 | 453 |
| Working capital days | −22 | 31 | 93 | 51 | 13 | −53 | −95 |
| ROCE % | — | 113.7% | 48.4% | 42.0% | 12.7% | −0.3% | 6.1% |
For the Mar 2026 quarter, Docmode Health Technologies reported sales of ₹7.64 Cr, down 64.1% year on year and net profit of −₹0.06 Cr. The operating margin was −15.2%.
Docmode Health Technologies' sales for the year to Mar 2026 were ₹25.31 Cr.
Net profit for the year to Mar 2026 was −₹0.12 Cr. Earnings per share over the same trailing period were ₹−0.40.
Docmode Health Technologies reported borrowings of ₹3.72 Cr at Mar 2026, against cash and equivalents of ₹0.17 Cr.
Cash from operations was ₹4.29 Cr in the year to Mar 2026; after capital spending, free cash flow was ₹2.41 Cr.